Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cadisegliatin 800 mg QD, Placebo.
- Who it may be relevant to
- Registry conditions: Type 1 Diabetes (T1D). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Hybrid CATT1: Hybrid Closed Loop Insulin Pumps With Cadisegliatin as Adjunctive Treatment in Patients With Type 1 Diabetes A Phase 2a Double Blind Randomized Cross-Over Study
Overview
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manager their diabetes. Patients using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 1-2 weeks followed by the second double-blind treatment period of 6 weeks where the patient will cross-over to the treatment arm that they did not receive in the first treatment period.
Detailed description
TTP399-206 is a 20 week, Phase 2a trial designed to evaluate efficacy and safety of cadisegliatin in participants with T1D who are using hybrid closed loop (HCL) systems to manage their condition to gather preliminary data to understand how cadisegliatin performs in an HCL setting.
Interventions
- Drug Cadisegliatin 800 mg QD
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin - Drug Placebo
Placebo (insulin alone)
Primary outcome measures
- To assess the change in Time in Range (TIR) [Time frame: last 2 weeks of the two 6-week treatment periods]
Secondary outcome measures (12)
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- CGM-based metric for glycemic control [Time frame: last 2 weeks of the two 6-week treatment periods]
- Change in glucose control after standardized mixed meal tolerance test (MMTT) [Time frame: 12 weeks]
- Change in glucose control after standardized mixed meal tolerance test (MMTT) [Time frame: 12 weeks]
- Change in glucose control after a standardized exercise test [Time frame: 12 weeks]
- Change in glucose control after a standardized exercise test [Time frame: 12 weeks]
- Change in glucose control after a standardized exercise test [Time frame: 12 weeks]
- To assess the change in Level 1, Level 2 , and Level 3 hypoglycemic incidence [Time frame: 12 weeks]
Eligibility criteria
Inclusion criteria
- Participants >= 18 years of age
- Fasting plasma C-peptide levels <0.6 ng/ml
- Average TIR < 70% at the end of the screening period
- Currently on a hybrid closed loop device for at least 3 months and willing to stay on the same model of pump device for study duration
- Willing to wear a study provided CGM for study duration
- Capable of participating in a 30-minute lasting exercise test
Exclusion criteria
- Have Type 2 Diabetes Mellitus (DM), monogenic diabetes, maturity-onset diabetes, other unusual or rare forms of DM, or diabetes resulting from a secondary disease.
- Have been hospitalized for DKA within 3 months
- Have uncontrolled hypothyroidism or hyperthyroidism
- Have QTcF interval > 450 msec for males or > 470 msec for females
- Have a personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias
- Have persistent, uncontrolled hypertension
- Have clinically significant cardiovascular or cerebrovascular disease
- Have proliferative retinopathy or maculopathy requiring acute treatment
- Have a serious concomitant systemic disorder incliuding but not limited to HIV or active Hep B or Hep C
- Diagnosed and/or treated for malignancy within 3 years
- Have used any of the following medications within the specified time periods: any non-insulin anti-diabetic therapies (e.g.SGLT-2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, DPP-4 inhibitors, pramlintide, a-glucosidase inhibitors, or glucose dependent insulinotropic polypeptide agonists) within 30 days, antipsychotic medications (e.g. olanzapine, risperidone, clozapine, quetiapine, and haloperidol) within 30 days, systemic corticosteroids for ≥7 days for a temporary medical condition within 30 days,
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Atlanta Diabetes Associates — Atlanta
Identifiers
NCT: NCT07616206 · TTP399-206